

---

**From:** Dolsten, Mikael (b) (6) >

**Sent:** Sunday, May 3, 2020 6:26 PM

**To:** Collins, Francis (NIH/OD) [E] (b) (6) >

**Subject:** Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below

(b) (4)

I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice  
Mikael

Mikael Dolsten, M.D., Ph.D.  
Chief Scientific Officer and President,  
Worldwide Research, Development and Medical  
Pfizer Inc.  
235 East 42nd Street  
New York, NY 10017

On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E]

(b) (6) > wrote:

Mats